HR 2521

Cavernous Angioma Research Resource Act of 2013

Congress: 113 (2013–2015, Ended)
Chamber: House
Policy Area: Health
Introduced: Jun 26, 2013
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (Jun 28, 2013)
Official Text: https://www.congress.gov/bill/113th-congress/house-bill/2521

Sponsor

Name: Rep. Lujan, Ben Ray [D-NM-3]
Party: Democratic • **State:** NM • **Chamber:** Senate

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Lujan Grisham, Michelle [D-NM-1]	D · NM		Jun 26, 2013
Rep. Pearce, Stevan [R-NM-2]	R · NM		Jun 26, 2013
Rep. Matheson, Jim [D-UT-4]	D · UT		Nov 14, 2013
Rep. Fattah, Chaka [D-PA-2]	D · PA		Jun 24, 2014

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 28, 2013

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
113 S 1223	Identical bill	**Jun 26, 2013:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Jun 26, 2013)

Cavernous Angioma Research Resource Act of 2013 - Amends the Public Health Service Act to require the Director of the National Institutes of Health (NIH), acting through the Director of the National Institute of Neurological Disorders and Stroke, to expand and intensify NIH programs regarding research and related activities concerning cavernous angioma. Authorizes grants and cooperative agreements to public or nonprofit private entities for such activities.

Authorizes the Director of NIH to: (1) conduct basic, clinical, and translational research on cavernous angioma; (2) identify and support the development of a clinical and research coordinating center with the potential of coordinating a multi-site clinical drug trial for cavernous angioma; and (3) identify and support the development of clinical and research participation centers with the potential to participate in such a trial.

Requires coordinating and participation centers to expand training programs for medical and allied health clinicians and scientists in clinical practice and research relevant to cavernous angioma.

Authorizes the Director to provide for the participation of NIH agencies in a consortium (to include at least one patient advocacy organization) to facilitate the exchange of information and increase the efficiency and effectiveness of the research effort.

Authorizes the Secretary of Health and Human Services (HHS) to award grants and cooperative agreements, including technical assistance, to public or nonprofit private entities for: (1) the collection, analysis, and reporting of data on cavernous angioma; and (2) epidemiological activities, including collecting and analyzing information on the number, incidence, correlates, and symptoms of cases and the clinical utility of specific practice patterns. Requires establishment of a national surveillance program as part of such activities.

Requires the Commissioner of Food and Drugs (FDA) to: (1) work with clinical centers, investigators, and advocates to support appropriate investigational new drug applications under the Federal Food, Drug, and Cosmetic Act in order to hasten the pace of clinical trials for cavernous angioma; and (2) where applicable in rare subpopulations of cavernous angioma requiring unique pharmacological intervention, including those with the Common Hispanic Mutation or CCM3 gene mutations, support appropriate requests for designations of orphan drugs.

Actions Timeline

- **Jun 28, 2013:** Referred to the Subcommittee on Health.
- **Jun 26, 2013:** Introduced in House
- **Jun 26, 2013:** Referred to the House Committee on Energy and Commerce.